Key result
Telcagepant shows noninferiority to placebo for treadmill exercise time in stable angina.
Why the study?
Does telcagepant reduce treadmill exercise time in patients with stable angina?
Population
60 patients with stable angina and reproducible exercise-induced angina.
Comparison
Telcagepant administered 2.5 hours before… vs Placebo.
Design
RCT, Randomized, two-period, crossover, Double-blind
Follow-up
2.5 hours after dose
Authors
Loading...
Supports safe use of telcagepant in stable angina without worsening exercise tolerance; confirms cardiovascular safety of CGRP receptor antagonism.
RCT (n=60)
double-blind
randomized
Does telcagepant reduce treadmill exercise time in patients with stable angina?
Mean Difference: -6.9 (95% CI -17.66–3.86)
Supratherapeutic doses of the CGRP receptor antagonist telcagepant do not significantly reduce treadmill exercise time in patients with stable angina, suggesting it does not worsen exercise-induced ischemia.
Chaitman et al. (2012) conducted an RCT in stable angina and reproducible exercise-induced angina (n=60). Telcagepant vs. Placebo was evaluated on treadmill exercise time (TET) (MD -6.90 seconds, 95% CI -17.66 to 3.86). Telcagepant was noninferior to placebo for treadmill exercise time in patients with stable angina (mean difference -6.90 seconds; 90% CI -17.66 to 3.86).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: